Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MB | P02144 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23771217 | 0.89 | RAB9A (0.67) | RAB9ASMN1; SMN2HTTL3MBTL1SRC | |
| SCHEMBL2023219 | 0.84 | SRC (0.63) | RAB9ASMN1; SMN2SRCNPC1MEN1 | |
| SCHEMBL29622963 | 0.84 | AOC3 (0.67) | RAB9ASMN1; SMN2HTTL3MBTL1NPC1 | |
| SCHEMBL4113855 | 0.84 | RAB9A (0.79) | RAB9ASMN1; SMN2HTTSRCNPC1 | |
| SCHEMBL274924 | 0.84 | TSHR (0.79) | RAB9ASMN1; SMN2HTTL3MBTL1NPC1 | |
| SCHEMBL29622962 | 0.84 | AOC3 (0.67) | RAB9ASMN1; SMN2HTTL3MBTL1NPC1 | |
| SCHEMBL7211903 | 0.83 | AOC3 (0.61) | RAB9ASMN1; SMN2HTTL3MBTL1TSHR | |
| SCHEMBL861674 | 0.83 | SMN1; SMN2 (0.84) | RAB9ASMN1; SMN2HTTL3MBTL1NPC1 | |
| SCHEMBL1014074 | 0.83 | SMN1; SMN2 (0.61) | RAB9ASMN1; SMN2HTTL3MBTL1NPC1 | |
| SCHEMBL839533 | 0.83 | SMN1; SMN2 (0.61) | RAB9ASMN1; SMN2HTTL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773221-B | P-benzoquinone compound and preparation method thereof | 湖北工业大学 | 2023-09-29 | — | — | CN | claimed |
| CN-113773221-A | P-benzoquinone compound and preparation method thereof | 湖北工业大学 | 2021-12-10 | — | — | CN | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-5849746-A | Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-12-15 | — | — | US | claimed |
| JP-63125571-A | — | — | None | — | — | JP | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-3749355-B1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIV MIAMI (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118063332-A | Preparation method of 2-hydroxy-4-ethylaniline and hydrochloride thereof | 浙江鼎龙科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
| US-3992378-A | HYPNOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3962440-A | Quinoxaline compounds as hypnotic agents | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885SMN1; SMN2 289/4885HTT 241/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | RAB9A 1140/4885SMN1; SMN2 2423/4885HTT 3879/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | RAB9A 2035/4885SMN1; SMN2 878/4885HTT 2657/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | RAB9A 1619/4885SMN1; SMN2 272/4885HTT 249/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885SMN1; SMN2 289/4885HTT 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.